Fibroblast growth factor-2 mediates transforming growth factor-Β action in prostate cancer reactive stroma

F. Yang, D. W. Strand, D. R. Rowley

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Transforming growth factor-β (TGF-β) is overexpressed at sites of wound repair and in most adenocarcinomas including prostate cancer. In stromal tissues, TGF-β regulates cell proliferation, phenotype and matrix synthesis. To address mechanisms of TGF-β action in cancer-associated reactive stroma, we developed prostate stromal cells null for TGF-β receptor II (TβRII) or engineered to express a dominant-negative Smad3 to attenuate TGF-β signaling. The differential reactive stroma (DRS) xenograft model was used to evaluate altered stromal TGF-β signaling on LNCaP tumor progression. LNCaP xenograft tumors constructed with TβRII null or dominant-negative Smad3 stromal cells exhibited a significant reduction in mass and microvessel density relative to controls. Additionally, decreased cellular fibroblast growth factor-2 (FGF-2) immunostaining was associated with attenuated TGF-β signaling in stroma. In vitro, TGF-β stimulated stromal FGF-2 expression and release. However, stromal cells with attenuated TGF-β signaling were refractory to TGF-β-stimulated FGF-2 expression and release. Re-expression of FGF-2 in these stromal cells in DRS xenografts resulted in restored tumor mass and microvessel density. In summary, these data show that TGF-β signaling in reactive stroma is angiogenic and tumor promoting and that this effect is mediated in part through a TβRII/Smad3-dependent upregulation of FGF-2 expression and release.

Original languageEnglish (US)
Pages (from-to)450-459
Number of pages10
JournalOncogene
Volume27
Issue number4
DOIs
StatePublished - Jan 17 2008

Fingerprint

Transforming Growth Factors
Fibroblast Growth Factor 2
Prostatic Neoplasms
Stromal Cells
Heterografts
Neoplasms
Microvessels
Specific Gravity
Growth Factor Receptors
Prostate
Adenocarcinoma
Up-Regulation
Cell Proliferation
Phenotype

Keywords

  • Angiogenesis
  • Fibroblast growth factor
  • Prostate cancer
  • Stroma
  • Transforming growth factor-β

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Fibroblast growth factor-2 mediates transforming growth factor-Β action in prostate cancer reactive stroma. / Yang, F.; Strand, D. W.; Rowley, D. R.

In: Oncogene, Vol. 27, No. 4, 17.01.2008, p. 450-459.

Research output: Contribution to journalArticle

@article{f4bc8e07619e470bb4fc8f7ce259f3d1,
title = "Fibroblast growth factor-2 mediates transforming growth factor-Β action in prostate cancer reactive stroma",
abstract = "Transforming growth factor-β (TGF-β) is overexpressed at sites of wound repair and in most adenocarcinomas including prostate cancer. In stromal tissues, TGF-β regulates cell proliferation, phenotype and matrix synthesis. To address mechanisms of TGF-β action in cancer-associated reactive stroma, we developed prostate stromal cells null for TGF-β receptor II (TβRII) or engineered to express a dominant-negative Smad3 to attenuate TGF-β signaling. The differential reactive stroma (DRS) xenograft model was used to evaluate altered stromal TGF-β signaling on LNCaP tumor progression. LNCaP xenograft tumors constructed with TβRII null or dominant-negative Smad3 stromal cells exhibited a significant reduction in mass and microvessel density relative to controls. Additionally, decreased cellular fibroblast growth factor-2 (FGF-2) immunostaining was associated with attenuated TGF-β signaling in stroma. In vitro, TGF-β stimulated stromal FGF-2 expression and release. However, stromal cells with attenuated TGF-β signaling were refractory to TGF-β-stimulated FGF-2 expression and release. Re-expression of FGF-2 in these stromal cells in DRS xenografts resulted in restored tumor mass and microvessel density. In summary, these data show that TGF-β signaling in reactive stroma is angiogenic and tumor promoting and that this effect is mediated in part through a TβRII/Smad3-dependent upregulation of FGF-2 expression and release.",
keywords = "Angiogenesis, Fibroblast growth factor, Prostate cancer, Stroma, Transforming growth factor-β",
author = "F. Yang and Strand, {D. W.} and Rowley, {D. R.}",
year = "2008",
month = "1",
day = "17",
doi = "10.1038/sj.onc.1210663",
language = "English (US)",
volume = "27",
pages = "450--459",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Fibroblast growth factor-2 mediates transforming growth factor-Β action in prostate cancer reactive stroma

AU - Yang, F.

AU - Strand, D. W.

AU - Rowley, D. R.

PY - 2008/1/17

Y1 - 2008/1/17

N2 - Transforming growth factor-β (TGF-β) is overexpressed at sites of wound repair and in most adenocarcinomas including prostate cancer. In stromal tissues, TGF-β regulates cell proliferation, phenotype and matrix synthesis. To address mechanisms of TGF-β action in cancer-associated reactive stroma, we developed prostate stromal cells null for TGF-β receptor II (TβRII) or engineered to express a dominant-negative Smad3 to attenuate TGF-β signaling. The differential reactive stroma (DRS) xenograft model was used to evaluate altered stromal TGF-β signaling on LNCaP tumor progression. LNCaP xenograft tumors constructed with TβRII null or dominant-negative Smad3 stromal cells exhibited a significant reduction in mass and microvessel density relative to controls. Additionally, decreased cellular fibroblast growth factor-2 (FGF-2) immunostaining was associated with attenuated TGF-β signaling in stroma. In vitro, TGF-β stimulated stromal FGF-2 expression and release. However, stromal cells with attenuated TGF-β signaling were refractory to TGF-β-stimulated FGF-2 expression and release. Re-expression of FGF-2 in these stromal cells in DRS xenografts resulted in restored tumor mass and microvessel density. In summary, these data show that TGF-β signaling in reactive stroma is angiogenic and tumor promoting and that this effect is mediated in part through a TβRII/Smad3-dependent upregulation of FGF-2 expression and release.

AB - Transforming growth factor-β (TGF-β) is overexpressed at sites of wound repair and in most adenocarcinomas including prostate cancer. In stromal tissues, TGF-β regulates cell proliferation, phenotype and matrix synthesis. To address mechanisms of TGF-β action in cancer-associated reactive stroma, we developed prostate stromal cells null for TGF-β receptor II (TβRII) or engineered to express a dominant-negative Smad3 to attenuate TGF-β signaling. The differential reactive stroma (DRS) xenograft model was used to evaluate altered stromal TGF-β signaling on LNCaP tumor progression. LNCaP xenograft tumors constructed with TβRII null or dominant-negative Smad3 stromal cells exhibited a significant reduction in mass and microvessel density relative to controls. Additionally, decreased cellular fibroblast growth factor-2 (FGF-2) immunostaining was associated with attenuated TGF-β signaling in stroma. In vitro, TGF-β stimulated stromal FGF-2 expression and release. However, stromal cells with attenuated TGF-β signaling were refractory to TGF-β-stimulated FGF-2 expression and release. Re-expression of FGF-2 in these stromal cells in DRS xenografts resulted in restored tumor mass and microvessel density. In summary, these data show that TGF-β signaling in reactive stroma is angiogenic and tumor promoting and that this effect is mediated in part through a TβRII/Smad3-dependent upregulation of FGF-2 expression and release.

KW - Angiogenesis

KW - Fibroblast growth factor

KW - Prostate cancer

KW - Stroma

KW - Transforming growth factor-β

UR - http://www.scopus.com/inward/record.url?scp=38349105902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349105902&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1210663

DO - 10.1038/sj.onc.1210663

M3 - Article

C2 - 17637743

AN - SCOPUS:38349105902

VL - 27

SP - 450

EP - 459

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 4

ER -